Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Small Cell Lung Cancer (SCLC): early-phase trial registry
10 of 13 indexed Small Cell Lung Cancer (SCLC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 10 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Small Cell Lung Cancer (SCLC): 13 US clinical trials tracked, 10 recruiting.
Small Cell Lung Cancer (SCLC) is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 10 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is Amgen, running 2 of these trials.
Enrollment posture brief
Registry condition small-cell-lung-cancer-sclc
OPEN 10 | RECR 77% | LATE 2 | EARLY 11 | RANK #1315 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Firearm Injury (77% recruiting · 13 trials)
Small Cell Lung Cancer (SCLC) lists 10 open slots (77% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Small Cell Lung Cancer (SCLC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Small Cell Lung Cancer (SCLC) is recruiting above its size-band peers.
10 of 13 indexed trials (76.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Small Cell Lung Cancer (SCLC) research.
Amgen accounts for 2 of 13 trials (15.4%). 11 distinct sponsors appear on at least one study for this condition label.
-
Typical Small Cell Lung Cancer (SCLC) enrolment sits around 150 participants.
Median target enrolment is 150 among the 13 trials that report a genuine target (sentinel values excluded). 4 of those (30.8%) plan for fewer than 100 participants.
-
Small Cell Lung Cancer (SCLC) research is mostly interventional.
13 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
NCT07226999
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Pfizer
NCT03460977
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phanes Therapeutics
NCT05652686
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Tasca Therapeutics
NCT07030257
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Molecular Partners
NCT07278479
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co.
NCT05490472
Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer
Alliance Foundation Trials
NCT07149363
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy
Abdera Therapeutics
NCT06736418
177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Radiopharm Theranostics
NCT07189871
SG and Immunotherapy as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer
Bindu R Potugari
NCT07339059
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
Amgen
NCT05740566
A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC
Amgen
NCT06745323
Prospective Clinicogenomic Program
Genentech
NCT04180176
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 4 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Small Cell Lung Cancer (SCLC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Small Cell Lung Cancer (SCLC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Small Cell Lung Cancer (SCLC) page
13 registered trials, 10 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 10 Small Cell Lung Cancer (SCLC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Amgen sponsors the most Small Cell Lung Cancer (SCLC) trials on record, review their full trial history before evaluating a specific study. See Amgen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Small Cell Lung Cancer (SCLC) condition card totals 13 registered trials; most-linked intervention Tarlatamab; top US site state Michigan. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.